NLS Pharmaceutics AG (NLSP)

Market Cap	3.16M
Revenue (ttm)	n/a
Net Income (ttm)	-6.60M
Shares Out	1.62M
EPS (ttm)	-6.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	257,839
Open	2.230
Previous Close	2.380
Day's Range	1.780 - 2.240
52-Week Range	1.730 - 24.320
Beta	-0.53
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 31, 2024

About NLSP

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nola...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 29, 2021
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: NLSP
• Website: https://nlspharma.com